Effects of diflunisal on platelet function and fecal blood loss. 1981

D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao

The effects of diflunisal, a nonacetylated difluorinated salicylate, on platelet function were compared with those of aspirin and placebo. In a randomized, double-blind trial, normal subjects were given diflunisal, 250, 500, or 1,000 mg twice daily; aspirin, 650 or 1,300 mg twice daily; or placebo for 8-day periods. Difunisal, 250 mg, had no effect on platelet function, whereas 500 mg induced minimal inhibition of colagen-induced release of platelet serotonin, and 1,000 mg inhibited platelet malondialdehyde production, moderately prolonged template bleeding times (P = NS), and increased fecal blood loss (P less than 0.05). In contrast, aspirin, 650 mg, markedly inhibited collagen-induced platelet aggregation and serotonin release, and 1,300 mg prolonged bleeding time (P less than 0.01) and increased fecal blood loss (P less than 0.01). The effects of aspirin lasted for up to 5 days, whereas changes induced by diflunisal had returned to baseline 24 hr after the drug was discontinued. We conclude that in doses in the same range as those of aspirin diflunisal inhibits platelet function less.

UI MeSH Term Description Entries
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010979 Platelet Function Tests Laboratory examination used to monitor and evaluate platelet function in a patient's blood. Function Test, Platelet,Function Tests, Platelet,Platelet Function Test,Test, Platelet Function,Tests, Platelet Function
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004061 Diflunisal A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN. Apo-Diflunisal,Dolobid,Dolobis,Dolocid,MK-647,Novo-Diflunisal,Nu-Diflunisal,Apo Diflunisal,ApoDiflunisal,MK 647,MK647,Novo Diflunisal,NovoDiflunisal,Nu Diflunisal,NuDiflunisal
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005243 Feces Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM.

Related Publications

D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
February 1977, British journal of clinical pharmacology,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
March 1983, Pharmacotherapy,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
January 1983, Pharmacotherapy,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
November 1981, Die Medizinische Welt,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
June 1979, Lancet (London, England),
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
January 1985, Pharmatherapeutica,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
June 1978, Clinical pharmacology and therapeutics,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
June 1991, The Journal of thoracic and cardiovascular surgery,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
October 1982, Thrombosis and haemostasis,
D Green, and R O Davies, and G I Holmes, and H Kohl, and R B Lee, and N Reynolds, and F R Schmid, and C Ts'ao
January 1982, Reviews of infectious diseases,
Copied contents to your clipboard!